Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, today ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene e ...

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.

Precision BioSciences (NASDAQ:DTIL) shares rallied 20% premarket on Tuesday after it entered into a $17.5M global licensing deal with TG Therapeutic (NASDAQ:TGTX).Under the deal, TG Therapeutics ...

Precision Biosciences, Inc. Condensed Statements of Operations (In thousands, except share and per share amounts) (Unaudited) For the Three Months Ended September 30, ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00. Soumit Roy has given his Buy rating due to a ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS ®- based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced its latest program updates ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...